Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Regeneron Reports First Quarter 2024 Financial and Operating Results
2 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
10-K
2023 FY
Annual report
5 Feb 24
8-K
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
8-K
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Regeneron Reports Third Quarter 2023 Financial and Operating Results
2 Nov 23
8-K
Results of Operations and Financial Condition
5 Oct 23
SC TO-T/A
Third party tender offer statement (amended)
25 Sep 23
SC TO-T/A
Third party tender offer statement (amended)
12 Sep 23
8-K/A
Submission of Matters to a Vote of Security Holders
8 Sep 23
8-K
Departure of Directors or Certain Officers
8 Sep 23
SC TO-T/A
Third party tender offer statement (amended)
8 Sep 23
SC TO-T
Third party tender offer statement
25 Aug 23
SC TO-C
Information about tender offer
9 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Regeneron Reports Second Quarter 2023 Financial and Operating Results
3 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Jun 23
PX14A6G
Letter to shareholders
18 May 23
DEFA14A
Additional proxy soliciting materials
17 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Regeneron Reports First Quarter 2023 Financial and Operating Results
4 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
Departure of Directors or Certain Officers
17 Apr 23
8-K
Results of Operations and Financial Condition
10 Apr 23
8-K
Entry into a Material Definitive Agreement
29 Mar 23
10-K
2022 FY
Annual report
6 Feb 23
8-K
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
3 Feb 23
8-K
J.P. Morgan Healthcare Conference 2023 Strategy & Business Update 2 Leonard S. Schleifer, MD, PhD Co - Founder, President & Chief Executive Officer
9 Jan 23
8-K
Entry into a Material Definitive Agreement
20 Dec 22
UPLOAD
Letter from SEC
7 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Regeneron Reports Third Quarter 2022 Financial and Operating Results
3 Nov 22
CORRESP
Correspondence with SEC
7 Oct 22
Latest ownership filings
4
GEORGE L SING
6 May 24
4
Marion McCourt
3 May 24
4
ARTHUR F RYAN
3 May 24
144
Notice of proposed sale of securities
1 May 24
144
Notice of proposed sale of securities
1 May 24
4
GEORGE YANCOPOULOS
1 May 24
4
GEORGE YANCOPOULOS
1 May 24
4
ARTHUR F RYAN
3 Apr 24
4
Marion McCourt
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
ANDREW J MURPHY
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
ARTHUR F RYAN
5 Mar 24
4
Marion McCourt
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
JOSEPH J LAROSA
28 Feb 24
4
GEORGE L SING
28 Feb 24
4
NEIL STAHL
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Bonnie L Bassler
26 Feb 24
4
JOSEPH J LAROSA
26 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
GEORGE L SING
26 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
144
Notice of proposed sale of securities
23 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
4
GEORGE YANCOPOULOS
20 Feb 24
4
Plew Daniel P Van
16 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Plew Daniel P Van
13 Feb 24
4
GEORGE L SING
12 Feb 24
4
Christopher R. Fenimore
12 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
4
JOSEPH J LAROSA
9 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
144
Notice of proposed sale of securities
8 Feb 24